Physician profile
Mohammed Ismail
NPI 1477588747
$3,044.03
in general payments reported to CMS, 2019-2025
20 companies · $608 in 2025
The $608 reported for 2025 was more than what 81% of Addiction Medicine (Internal Medicine) providers received nationally (typical 2025 total: $124).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $440 · 2020: $111 · 2021: $150 · 2022: $382 · 2023: $878 · 2024: $476 · 2025: $608.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,947 · Education: $14.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,946.83 |
| Education | $14.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $513.10 | 2023-2025 | Brixadi |
| Astrazeneca Pharmaceuticals Lp | $488.11 | 2022-2023 | Farxiga, Breztri |
| Indivior INC. | $390.84 | 2019-2025 | Sublocade |
| Orexo US, INC. | $359.09 | 2019-2025 | Zubsolv |
| Boston Scientific Corporation | $284.09 | 2023 | Axios |
| Novo Nordisk INC | $181.12 | 2022-2025 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.18 | 2025 | Jardiance |
| Alkermes, INC. | $142.26 | 2022-2024 | Vivitrol |
| Gilead Sciences, INC. | $142.10 | 2021-2024 | Epclusa |
| Abbott Laboratories | $125.00 | 2025 | Freestyle Libre 3 |
| Teva Pharmaceuticals USA, INC. | $122.88 | 2023 | Uzedy |
| Madrigal Pharmaceuticals | $28.91 | 2025 | Rezdiffra |
| Lilly USA, LLC | $26.86 | 2023 | Mounjaro |
| Verona Pharma, INC. | $25.88 | 2025 | Ohtuvayre |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $22.51 | 2025 | Lifevest |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $21.54 | 2019 | |
| Neurocrine Biosciences, INC. | $20.56 | 2024 | Ingrezza |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Ismail listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.